The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business ...

The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

WITH all the buzz around the so-called ‘miracle’ weight-loss jabs Ozempic, you could easily mistake it for a cure for all.

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...

“The FTC’s administrative action seeks to put an end to the Big Three PBMs’ exploitative conduct and marks an important step ...

The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx ...

The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes ...

The three price benefit managers jointly administer 80% of all prescriptions in the U.S., the FTC said in the lawsuit.

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...